Antiviral Drugs Market Contributing Large Share
Market Overview:
Antiviral drugs are therapeutics used to treat infectious diseases caused by viruses such as influenza, hepatitis, herpes, HIV, and others. These drugs inhibit the replication of viruses inside host cells. The major classes of antiviral drugs include reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, and neuraminidase inhibitors. These drugs target specific stages of viral replication cycles to generate antiviral responses. The increasing need for therapeutics to treat life-threatening viral infections drives the growth of the antiviral drugs market.
Market key trends:
The increasing prevalence of viral infections have driven demand for more effective antiviral therapies over the past decade. One key trend gaining traction in the antiviral drugs market is the development of long-acting antiviral therapies. Companies are focusing on developing antiviral drugs that provide longer protection against viral infections compared to conventional short-acting drugs. For instance, GlaxoSmithKline's cabotegravir is a long-acting injectable HIV therapy developed to be administered every 2 months vs daily oral anti-retroviral regimens. Such formulation advances help drive patient adherence to treatment regimens.
Here is the sample Segment Analysis and Key Takeaways for the given Antiviral Drugs Market research report:
Segment Analysis
The global Antiviral Drugs Market Demand is segmented on the basis of drug class, indication, distribution channel, and region. Based on drug class, the market is segmented into protease inhibitors, reverse transcriptase inhibitors, nucleotide polymerase inhibitors, and others. The protease inhibitors segment dominated the market in 2021 owing to the wide availability of drugs classes such as ritonavir, lopinavir, and saquinavir used for treating HIV infection.
Key Takeaways
The global antiviral drugs market size is expected to witness high growth, exhibiting a CAGR of 4.2% over the forecast period from 2023-2030, due to increasing prevalence of viral infectious diseases such as HIV, hepatitis, influenza, and coronavirus. The market was valued at US$ 56,480.7 million in 2021.
Regional analysis - North America dominated the antiviral drugs market in 2021 and is expected to continue its dominance over the forecast period. This is attributed to the rising prevalence of viral diseases and growing R&D investments in antiviral drug development in the region. Asia Pacific is expected to witness the fastest growth over the forecast period owing to increasing healthcare expenditure and large patient pool suffering from viral infections in countries like China and India.
Key players - Key players operating in the antiviral drugs market are GlaxoSmithKline plc, AbbVie Inc., Merck & Co., Inc., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Cipla Inc., Aurobindo Pharma, and Gilead Sciences. Major players are focusing on new product launches, mergers, acquisitions and collaborations to gain a competitive edge in the market.
Read More:
https://www.dailyprbulletin.com/antiviral-drugs-market-demand-share-and-growth/
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian